Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Stable Cell State Engineering for Regulatory T Cell Therapies

Award Number: F32AI202861
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 02/26/2027
PERIOD OF PERFORMANCE END DATE: 02/25/2028

Group Awards By:

View Award Description

Stable Cell State Engineering for Regulatory T Cell Therapies - ABSTRACT Autoimmune diseases such as multiple sclerosis, type 1 diabetes, inflammatory bowel disease, and rheumatoid arthritis affect tens of millions of people and are largely managed with systemic immunosuppression that compromises host defense and rarely induces cure. Antigen-specific tolerance—retraining the immune system to ignore self while preserving protective immunity—is a major unmet need directly aligned with the NIH mission to reduce the burden of chronic, immune-mediated disease. This fellowship aims to engineer stable cell therapies for restoring antigen-specific tolerance. It will focus primarily on IL-10-expressing type 1 regulatory T (Tr1) cells because they emerge naturally in inflamed peripheral tissues to restrains pathogenic immune responses. Therefore, to achieve the overarching goal of engineering a stable Tr1 cell state, this proposal will first identify genetic perturbations that drive Tr1 differentiation (Aim 1) and then engineer solutions that stabilize it under inflammatory pressure (Aim 2). In Aim 1, the applicant will screen thousands of multi-gene knock-ins using state-of-the-art experimental approaches and then refine construct designs using advanced algorithms for perturbation modelling. By iteratively screening constructs and refining designs, Aim 1 will converge on solutions for Tr1 state engineering while comparing the effectiveness of two different strategies: “rationally designed” constructs (encoding putative Tr1-associated regulators) versus unbiased “diversity- oriented” constructs (synthetic transcription factors with mixed effector and DNA binding domains). In Aim 2, the applicant will engineer and screen cytokine switch receptors that convert common inflammatory cues into tolerogenic signals. Aim 2 will then test the ability of these synthetic receptors to preserve Tr1 identity and suppressive function under Th1-, Th17-, and Th2-like cytokine milieus in vitro and in humanized mouse models of colitis. Together, these studies will identify a translation-ready cell therapy candidate for autoimmunity while establishing design principles and a broadly applicable framework for “stable cell state engineering” in any context. The integrated research and training plan will provide rigorous mentoring in synthetic biology, dynamical modeling, clinical and translational immunology, and structured career development in grantsmanship, communication, and leadership. Successful completion of the research aims and training goals will directly support the applicant’s long-term career goal of leading an independent, NIH-funded research laboratory focused on cell state engineering and translatable therapies for inducing antigen-specific tolerance.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $76,300 )
2026	2026	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Allergy and Infectious Diseases Research	000	1	9/2/2026	NEW	$76,300
														Subtotal = $76,300

Grand Total All Awards = $76,300

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Stable Cell State Engineering for Regulatory T Cell Therapies

Award Number: F32AI202861

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 02/26/2027

PERIOD OF PERFORMANCE END DATE: 02/25/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer